REMEDUS PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
REMEDUS PHARMA
Largest movements
- Tangible fixed assets +€83,017
up €83,017 (+2.6%), from €3.2m to €3.3m
of which Assets under construction and advance payments: +€236,820
- Profit (loss) carried forward -€327,197
down €327,197 (-191%), from -€171,105 to -€498,302
- Other debts +€318,039
up €318,039 (+11.5%), from €2.8m to €3.1m
- Tax, wage and social debts +€38,671
up €38,671 (+178%), from €21,739 to €60,409
- Gross operating margin -€116,773
down €116,773, from €30,695 to -€86,078
- Depreciation +€83,064
up €83,064 (+109%), from €75,927 to €158,991
- Other operating charges +€5,830
up €5,830 (+49.6%), from €11,757 to €17,588
- Financial charges -€1,509
down €1,509 (-2.3%), from €66,078 to €64,569
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,273,153 | €3,333,698 | +€60,545 | +1.8% |
| Fixed assets | 21/28 | €3,224,877 | €3,307,894 | +€83,017 | +2.6% |
| Tangible fixed assets | 22/27 | €3,224,877 | €3,307,894 | +€83,017 | +2.6% |
| Land and buildings | 22 | €2,899,512 | €2,790,473 | -€109,039 | -3.8% |
| Plant, machinery and equipment | 23 | €14,083 | €8,565 | -€5,518 | -39.2% |
| Furniture and vehicles | 24 | €65,118 | €57,677 | -€7,441 | -11.4% |
| Other tangible fixed assets | 26 | €246,163 | €214,359 | -€31,805 | -12.9% |
| Assets under construction and advance payments | 27 | €0 | €236,820 | +€236,820 | |
| Current assets | 29/58 | €48,276 | €25,804 | -€22,472 | -46.5% |
| Amounts receivable within one year | 40/41 | €1,061 | €9,778 | +€8,717 | +822% |
| Trade receivables | 40 | €0 | - | = | |
| Other amounts receivable | 41 | €1,061 | €9,778 | +€8,717 | +822% |
| Cash at bank and in hand | 54/58 | €46,053 | €15,443 | -€30,610 | -66.5% |
| Deferred charges and accrued income | 490/1 | €1,162 | €584 | -€579 | -49.8% |
| Total equity and liabilities | 10/49 | €3,273,153 | €3,333,698 | +€60,545 | +1.8% |
| Equity | 10/15 | -€53,714 | -€380,911 | -€327,197 | -609% |
| Contributions | 10/11 | €114,200 | €114,200 | = | 0.0% |
| Reserves | 13 | €3,192 | €3,192 | = | 0.0% |
| Non-distributable reserves | 130/1 | €3,192 | €3,192 | = | 0.0% |
| Reserves not available under the articles | 1311 | €3,192 | €0 | -€3,192 | -100% |
| Other | 1319 | - | €3,192 | +€3,192 | |
| Profit (loss) carried forward | 14 | -€171,105 | -€498,302 | -€327,197 | -191% |
| Amounts payable | 17/49 | €3,326,867 | €3,714,609 | +€387,742 | +11.7% |
| Amounts payable after more than one year | 17 | €500,000 | €500,000 | = | 0.0% |
| Financial debts | 170/4 | €500,000 | €500,000 | = | 0.0% |
| Amounts payable within one year | 42/48 | €2,782,467 | €3,141,084 | +€358,617 | +12.9% |
| Trade debts | 44 | €3,767 | €5,675 | +€1,908 | +50.7% |
| Suppliers | 440/4 | €3,767 | €5,675 | +€1,908 | +50.7% |
| Taxes, remuneration and social security | 45 | €21,739 | €60,409 | +€38,671 | +178% |
| Taxes | 450/3 | €21,739 | €60,409 | +€38,671 | +178% |
| Other amounts payable | 47/48 | €2,756,961 | €3,075,000 | +€318,039 | +11.5% |
| Accrued charges and deferred income | 492/3 | €44,400 | €73,525 | +€29,125 | +65.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €75,927 | €158,991 | +€83,064 | +109% |
| Other operating charges | 640/8 | €11,757 | €17,588 | +€5,830 | +49.6% |
| Gross operating margin | 9900 | €30,695 | -€86,078 | -€116,773 | |
| Operating profit (loss) | 9901 | -€56,990 | -€262,657 | -€205,667 | -361% |
| Financial income | 75/76B | €45 | €378 | +€334 | +747% |
| Recurring financial income | 75 | €45 | €378 | +€334 | +747% |
| Financial charges | 65/66B | €66,078 | €64,569 | -€1,509 | -2.3% |
| Recurring financial charges | 65 | €66,078 | €64,569 | -€1,509 | -2.3% |
| Profit (loss) for the period before taxes | 9903 | -€123,023 | -€326,847 | -€203,824 | -166% |
| Income taxes | 67/77 | €348 | €350 | +€2 | +0.6% |
| Profit (loss) for the period | 9904 | -€123,371 | -€327,197 | -€203,826 | -165% |
| Profit (loss) for the period to be appropriated | 9905 | -€123,371 | -€327,197 | -€203,826 | -165% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.